investor.dendreon.com investor.dendreon.com

investor.dendreon.com

Dendreon Corporation - News and Information

Medical Affairs Web site. Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients. View all ». Feb 10, 2015. Dendreon Announces Expiration of Bid Deadline In Connection With Agreement to Sell Substantially All Assets to Valeant. Feb 5, 2015. Jan 29, 2015. Stipulation of Settlement of Certain Shareholder Litigation.

http://investor.dendreon.com/

WEBSITE DETAILS
SEO
PAGES
SIMILAR SITES

TRAFFIC RANK FOR INVESTOR.DENDREON.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

June

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Friday

TRAFFIC BY CITY

CUSTOMER REVIEWS

Average Rating: 4.2 out of 5 with 10 reviews
5 star
8
4 star
0
3 star
0
2 star
0
1 star
2

Hey there! Start your review of investor.dendreon.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

Desktop Preview Tablet Preview Mobile Preview

LOAD TIME

CONTACTS AT INVESTOR.DENDREON.COM

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

SCORE

6.2

PAGE TITLE
Dendreon Corporation - News and Information | investor.dendreon.com Reviews
<META>
DESCRIPTION
Medical Affairs Web site. Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients. View all ». Feb 10, 2015. Dendreon Announces Expiration of Bid Deadline In Connection With Agreement to Sell Substantially All Assets to Valeant. Feb 5, 2015. Jan 29, 2015. Stipulation of Settlement of Certain Shareholder Litigation.
<META>
KEYWORDS
1 restructuring info
2 site map
3 about us
4 patient resources
5 research and development
6 news and information
7 careers
8 share this on
9 delicious
10 digg
CONTENT
Page content here
KEYWORDS ON
PAGE
restructuring info,site map,about us,patient resources,research and development,news and information,careers,share this on,delicious,digg,facebook,linkedin,twitter,what is this,governance,press releases,financial restructuring,media information,media
CONTENT-TYPE
utf-8
GOOGLE PREVIEW

Dendreon Corporation - News and Information | investor.dendreon.com Reviews

https://investor.dendreon.com

Medical Affairs Web site. Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients. View all ». Feb 10, 2015. Dendreon Announces Expiration of Bid Deadline In Connection With Agreement to Sell Substantially All Assets to Valeant. Feb 5, 2015. Jan 29, 2015. Stipulation of Settlement of Certain Shareholder Litigation.

LINKS TO THIS WEBSITE

dendreon.com dendreon.com

PROVENGE - Dendreon.com

http://www.dendreon.com/products/provenge

Medical Affairs Web site. Sipuleucel-T) Is FDA Approved. PROVENGE is the first and only FDA approved immunotherapy. Treatment that helps the immune system (the body’s natural defense) fight disease. For advanced prostate cancer. PROVENGE is the only personalized treatment that is clinically proven to help extend life in certain men with advanced prostate cancer. PROVENGE is an immunotherapy. Treatment that helps the immune system (the body’s natural defense) fight disease. PROVENGE is an immunotherapy.

dendreon.com dendreon.com

Cancer Treatment - Apoptosis - Dendreon.com

http://www.dendreon.com/products/provenge/manufacturing

Medical Affairs Web site. The manufacturing of PROVENGE. Sipuleucel-T) is conducted at facilities in Orange County, California and Atlanta, Georgia. See how PROVENGE is manufactured and designed to work by viewing a brief video.

dendreon.com dendreon.com

Cancer Therapy - Dendreon.com

http://www.dendreon.com/products

Medical Affairs Web site. PAVING A NEW PATH FOR TREATING CANCER. Sipuleucel-T) is the first autologous cellular immunotherapy. PROVENGE is classified by the FDA as an autologous cellular immunotherapy. It is designed to be an active cellular immunotherapy. To receive FDA approval for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. PROVENGE is designed to take the body’s own immune cells and reprogram them to attack advanced prostate cancer.

UPGRADE TO PREMIUM TO VIEW 1 MORE

TOTAL LINKS TO THIS WEBSITE

4

SOCIAL ENGAGEMENT



OTHER SITES

investor.daily.co.uk investor.daily.co.uk

Daily Investors

Annualised revenue per service per customer starts. At 259 for domain registration services up to 350k for. A PCI DSS Hosting cluster (‘Payment Card Industry Data. Now provides a broad range of infrastructure and cloud based services. To individuals, small to medium enterprises ( SMEs ) and larger corporates. To become the one-stop supplier of reliable, scalable, high performance. And resilient infrastructure based hosting products. OUR BUSINESS STATISTICS and INFORMATION.

investor.daktronics.com investor.daktronics.com

Investor Relations | Daktronics, Inc.

Skip to main navigation. Out of Home Advertising. Digit and Price Displays. ITS Dynamic Message Signs. Annual Reports and Proxy. Annual Reports and Proxy. News and Event Alerts. Daktronics designs, manufactures, sells and services dynamic visual communication systems for customers worldwide. Daktronics is a public corporation whose stock is traded on the Nasdaq national market under the symbol DAKT. Mar 28, 2018. Daktronics Unveils Major Innovation For Traffic Applications. Mar 27, 2018. Mar 02, 2018.

investor.darden.com investor.darden.com

Darden Restaurants, Inc. - Investors - Investor Relations

Doing Business With Darden. Energy and Water Conservation. The Darden family of restaurants features some of the most recognizable and successful brands in full-service dining. Through subsidiaries, we own and operate more than 1,600 restaurants, employ 165,000 people and serve 380 million guests a year. Be financially successful through great people consistently delivering outstanding food, drinks and service in an inviting atmosphere, making every guest loyal! March 22, 2018. February 26, 2018. Darden ...

investor.deere.com investor.deere.com

Q4 Web Site Development

Q4 Web Maintenance Message. This site is currently under development and not yet available for public viewing. For more information on why this site is not available, please contact Q4.

investor.delphi.com investor.delphi.com

Delphi - Login

We have emailed you instructions. We can help you reset your password using your email address linked to your account. Your full suite of IR tools in one unique platform. This site is protected by Two-Factor Authentication. Please download Google Authenticator from the App Store for iOS or the Play Store for Android. For other devices, download an authenticator app from your device store. Secret key (excluding spaces):. Enter the PIN to verify your identity. Need help? Remember this computer for 30.

investor.dendreon.com investor.dendreon.com

Dendreon Corporation - News and Information

Medical Affairs Web site. Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients. View all ». Feb 10, 2015. Dendreon Announces Expiration of Bid Deadline In Connection With Agreement to Sell Substantially All Assets to Valeant. Feb 5, 2015. Jan 29, 2015. Stipulation of Settlement of Certain Shareholder Litigation.

investor.dennys.com investor.dennys.com

Denny's Corporation - Investor Relations

Jan 9, 2017. Denny’s Corporation Releases Preliminary Financial Results for Fourth Quarter and Fiscal Year 2016. Jan 3, 2017. Denny’s Corporation to Present at the 19th Annual ICR Conference on January 10, 2017. Upcoming events are not available at this time. Sign up for email alerts. Stock Quote (NASDAQ: DENN). 11:29 on January 12, 2017 11:29 AM. Delayed at least 20 minutes. Jan 10, 2017. 19th Annual ICR Conference. Nov 1, 2016. Denny's Third Quarter 2016 Earnings Conference Call. Powered By Q4 Inc.

investor.dentsply.com investor.dentsply.com

DENTSPLY - Investor Relations - Investor Relations

Don’t have an account? Welcome to DENTSPLY International's Investor Relations web site. Whether you're a DENTSPLY investor or potential investor - or simply want to learn more about our Company - we hope you'll find the information here useful and interesting. If you would like to be included on our distribution list, please enter your email address in the space below. You may adjust your preferences under the email alerts tab. July 30, 2015. July 29, 2015. July 07, 2015. June 08, 2015. June 01, 2015.

investor.dentsplysirona.com investor.dentsplysirona.com

Dentsply Sirona - Investors - Investors

Press Releases and News. Welcome to Dentsply Sirona's Investor Relations web site. Whether you're a Dentsply Sirona investor or potential investor - or simply want to learn more about our Company - we hope you'll find the information here useful and interesting. Press Releases and News. Financial Information and Quarterly Results. 160;  0.82. Data as of 01/13/17 4:00 pm ET. Data provided by Nasdaq. Minimum 15 minutes delayed. VP, Investor Relations. VP, Investor Relations and Corporate Communications.

investor.depomedinc.com investor.depomedinc.com

Depomed - Investor Relations - Investors

Depomed Corporate Presentation August 7, 2015. Q2 2015 Depomed Earnings Conference Call. 160;at 4:30 pm ET. Depomed is a specialty pharmaceutical company focused on pain and other central nervous system conditions. We currently market FDA-approved products, NUCYNTA. The following are abbreviated descriptions of Depomed’s products:. Tapentadol) extended release tablets indicated, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alter...

investor.destinationmaternity.com investor.destinationmaternity.com

Investors | Destination Maternity® Corporation

Annual report and proxy statement. Destination Maternity Corporation is the world's largest designer and retailer of maternity apparel. In the United States and Canada, as of January 31, 2015, Destination Maternity operates 1,875 retail locations, including 564 stores, predominantly under the trade names Motherhood Maternity , A Pea in the Pod , and Destination Maternity , and 1,311. 160;  0.17. 08/07/15 4:00 pm ET. Data Provided by Thomson Reuters. A Pea in the Pod Opens Shop in Harrods. Notice and Prox...